2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107617
    PTIQ 1032822-42-6
    PTIQ can suppress MMP-3 production, can enter the brain and provide neuroprotection. PTIQ has anti-inflammatory effects on microglial cells.
    PTIQ
  • HY-107625
    SNAP 94847 487051-12-7
    SNAP 94847 is a novel, high affinity selective melanin-concentrating hormonereceptor1 (MCHR1) antagonist with (Ki= 2.2 nM, Kd=530 pM), it displays >80-fold and >500-fold selectivity over MCHα1A and MCHD2 receptors respectively. SNAP 94847 binds with high affinity to the mouse and rat MCHR1 with minimal cross-reactivity to other GPCR, ion channels, enzymes, and transporters.
    SNAP 94847
  • HY-107650
    Milameline hydrochloride 139886-04-7
    Milameline (CI 979) hydrochloride is a muscarinic receptor agonist that improves cognition.
    Milameline hydrochloride
  • HY-107652
    AF-DX 384 118290-26-9 98.0%
    AF-DX 384 is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine.
    AF-DX 384
  • HY-107653
    J 104129 fumarate 257603-40-0
    J 104129 fumarate is a selective and orally active muscarinic M3 antagonist with Ki values of 4.2 nM and 490 nM for M3 and M2, respectively. J 104129 fumarate antagonized ACh-induced bronchoconstriction. J 104129 fumarate has the potential for the research of obstructive airway disease.
    J 104129 fumarate
  • HY-107656
    PTAC oxalate 201939-40-4
    PTAC oxalate is a selective muscarinic receptor ligand. PTAC oxalate is an partial agonist of M2 and M4 but antagonist of M1, M3, and M5 (Ki values of 0.2-2.8 nM for hM1-5 in CHO cells). PTAC oxalate alleviates the mechanical allodynia on the neuropathic pain and has antidepression effects.
    PTAC oxalate
  • HY-107663
    MIF-1 2002-44-0
    MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects. MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB).
    MIF-1
  • HY-107666
    PHA 568487 527680-57-5
    PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR).PHA 568487 reduces neuroinflammation and oxidative stress. PHA-568487 has rapid brain penetration.
    PHA 568487
  • HY-107667
    TC-2559 fumarate 212332-35-9
    TC-2559 fumarate is a potent and selective neuronal acetylcholine receptor agonist. TC-2559 fumarate is potent and efficacious in the activation of CNS receptors and reduces glutamate-induced neurotoxicity in vitro.
    TC-2559 fumarate
  • HY-107669
    nAChR-IN-1 hydrochloride 849461-91-2
    nAChR-IN-1 (hydrochloride) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research.
    nAChR-IN-1 hydrochloride
  • HY-107671
    DMAB-anabaseine dihydrochloride 154149-38-9
    DMAB-anabaseine dihydrochloride is a selective nicotinic α7 receptor partial agonist and an α4β2 nAChR antagonist. DMAB-anabaseine dihydrochloride shows cognition-enhancing effects.
    DMAB-anabaseine dihydrochloride
  • HY-107673
    RJR-2429 dihydrochloride 1021418-53-0
    RJR 2429 hydrochloride is a α4β2 and α7 nAChR agonist.
    RJR-2429 dihydrochloride
  • HY-107677
    A 844606 861119-08-6
    A 844606 is a highly potent and selective α4β2 nAChR agonist. A 844606 can be used in the study of schizophrenia, Huntington's disease, Alzheimer's disease, and Parkinson's disease.
    A 844606
  • HY-107681
    SIB-1508Y 192231-16-6
    SIB-1508Y is an orally active and selective nAChR agonist. SIB-1508Y has the potential to study parkinsonism. SIB-1508Y is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    SIB-1508Y
  • HY-107683
    LY-2087101 913186-74-0
    LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region.
    LY-2087101
  • HY-107695
    Remacemide hydrochloride 111686-79-4
    Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na+ channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively. Remacemide hydrochloride is an anticonvulsant agent.
    Remacemide hydrochloride
  • HY-107696
    Ro 04-5595 hydrochloride 64047-73-0
    Ro 04-5595 hydrochloride is a GluN2B-selective NMDA receptor antagonist (Ki: 31 nM).
    Ro 04-5595 hydrochloride
  • HY-107697
    N20C hydrochloride 1177583-87-7
    N20C hydrochloride is a selective and noncompetitive open NMDA receptor open channel blocker, with micromolar affinity, fast on-off blockade kinetics, and strong voltage dependence. Neuroprotective activity.
    N20C hydrochloride
  • HY-107698
    PMPA (NMDA antagonist) 113919-36-1
    PMPA (NMDA antagonist) is an NMDA receptor antagonist with Ki values of 0.84, 2.74, 3.53 and 4.16 μM for NR2A, NR2B, NR2C and NR2D, respectively.
    PMPA (NMDA antagonist)
  • HY-107699
    PPPA 113190-92-4
    PPPA is a competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors.
    PPPA
Cat. No. Product Name / Synonyms Application Reactivity